Endo, Inc. Sets Annual Meeting for June 25, Focuses on Governance
| Field | Detail |
|---|---|
| Company | Endo, Inc. |
| Form Type | DEF 14A |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Corporate Governance, Shareholder Meeting, Executive Compensation, Pharmaceuticals, SEC Filing, Board of Directors
TL;DR
**Endo's proxy statement is a standard governance update; vote your shares to ensure your voice is heard on executive pay and board composition.**
AI Summary
Endo, Inc.'s DEF 14A filing, dated June 2, 2025, outlines the upcoming Annual Meeting of Stockholders on June 25, 2025, at 10:00 a.m. ET in Malvern, Pennsylvania. The filing primarily serves as a definitive proxy statement, indicating no fee was required for its submission. Key executive compensation data for the period of January 1, 2024, to December 31, 2024, is referenced, specifically for Mr. Hirsch and Mr. Coleman, covering equity awards granted and outstanding. While specific dollar amounts for revenue and net income are not detailed in this particular filing, the document focuses on corporate governance and shareholder voting matters. The strategic outlook emphasizes shareholder participation in the annual meeting, with Paul Herendeen serving as Chairman of the Board and Scott Hirsch as Interim Chief Executive Officer. The filing does not disclose specific business changes or risks beyond the standard proxy statement disclosures. The company's primary business is Pharmaceutical Preparations (SIC 2834).
Why It Matters
This DEF 14A filing is crucial for investors as it details the upcoming Annual Meeting of Stockholders, where key governance decisions, including director elections and executive compensation approvals, will be made. Shareholder participation is vital for holding management accountable and influencing the company's strategic direction in the competitive pharmaceutical preparations industry. For employees, the outcomes of these votes can impact leadership stability and long-term company strategy. Customers may see indirect effects through changes in product development or market focus, depending on the board's composition and priorities. The broader market will watch for any signals regarding Endo's stability and future operational plans.
Risk Assessment
Risk Level: low — The risk level is low because this DEF 14A is a routine definitive proxy statement for an annual meeting, primarily focused on corporate governance and shareholder voting. It does not disclose new financial risks, operational challenges, or significant strategic shifts, but rather outlines the process for the June 25, 2025, meeting.
Analyst Insight
Investors should review the full proxy statement to understand the proposals, especially regarding executive compensation for Mr. Hirsch and Mr. Coleman, and board nominations. Promptly cast your vote by June 25, 2025, to ensure your shares are represented and your preferences are registered on governance matters.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Scott Hirsch | Interim Chief Executive Officer | |
| Mr. Coleman | Member |
Key Numbers
- 2025-06-02 — Filing Date (Date the DEF 14A was filed with the SEC)
- 2025-06-25 — Annual Meeting Date (Date of Endo, Inc.'s Annual Meeting of Stockholders)
- 10:00 a.m. ET — Meeting Time (Scheduled start time for the Annual Meeting)
- 2024-01-01 — Compensation Period Start (Beginning of the period for which executive compensation data is referenced)
- 2024-12-31 — Compensation Period End (End of the period for which executive compensation data is referenced)
Key Players & Entities
- Endo, Inc. (company) — Registrant filing the DEF 14A
- Paul Herendeen (person) — Chairman of the Board for Endo, Inc.
- Scott Hirsch (person) — Interim Chief Executive Officer for Endo, Inc.
- Mr. Coleman (person) — Executive referenced in compensation tables for Endo, Inc.
- SEC (regulator) — Securities and Exchange Commission
- 9 Great Valley Parkway, Malvern, PA 19355 (location) — Business and meeting address for Endo, Inc.
- 0002008861 (company) — Central Index Key (CIK) for Endo, Inc.
- 03 Life Sciences (company) — Organization Name associated with the filing
- Pharmaceutical Preparations (company) — Standard Industrial Classification (SIC) for Endo, Inc.
- June 25, 2025 (date) — Date of the Annual Meeting of Stockholders
FAQ
When is Endo, Inc.'s Annual Meeting of Stockholders?
Endo, Inc.'s Annual Meeting of Stockholders is scheduled for June 25, 2025, at 10:00 a.m. ET. The meeting will be held at 9 Great Valley Parkway, Malvern, Pennsylvania 19355.
What is the purpose of Endo, Inc.'s DEF 14A filing?
The DEF 14A filing by Endo, Inc. is a definitive proxy statement, which provides shareholders with information necessary to make informed decisions regarding matters to be voted on at the Annual Meeting, such as director elections and executive compensation.
Who are the key executives mentioned in Endo, Inc.'s proxy statement?
The proxy statement mentions Paul Herendeen as the Chairman of the Board and Scott Hirsch as the Interim Chief Executive Officer. Mr. Coleman is also referenced in the context of executive compensation for the 2024 fiscal year.
What is Endo, Inc.'s primary business according to the filing?
According to the filing, Endo, Inc.'s Standard Industrial Classification (SIC) is 2834, which corresponds to Pharmaceutical Preparations. This indicates their primary business is in the pharmaceutical industry.
Does the DEF 14A filing include specific financial results for Endo, Inc.?
This particular DEF 14A filing, as a definitive proxy statement, does not detail specific revenue or net income figures. It primarily focuses on corporate governance, executive compensation disclosures for the 2024 fiscal year, and the agenda for the Annual Meeting.
How can shareholders vote for Endo, Inc.'s Annual Meeting?
Shareholders are encouraged to cast their vote promptly to ensure their shares are represented at the meeting. The filing states that options for voting are detailed in the full Proxy Statement.
What is the fiscal year end for Endo, Inc.?
Endo, Inc.'s fiscal year end is December 31, as indicated by the 'FISCAL YEAR END: 1231' in the filing header.
Are there any new risks disclosed in this Endo, Inc. DEF 14A?
This DEF 14A filing is a routine proxy statement for an annual meeting and does not disclose new or specific financial, operational, or strategic risks beyond the standard disclosures related to corporate governance and executive compensation.
What is the address of Endo, Inc.'s business operations?
Endo, Inc.'s business address is 9 Great Valley Parkway, Malvern, PA 19355. This is also the location for the upcoming Annual Meeting of Stockholders.
What period does the executive compensation data in the filing cover for Endo, Inc.?
The executive compensation data referenced in the filing, specifically for equity awards granted and outstanding for Mr. Hirsch and Mr. Coleman, covers the period from January 1, 2024, to December 31, 2024.
Industry Context
Endo, Inc. operates within the Pharmaceutical Preparations sector (SIC 2834). This industry is characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation, patent expirations, and market access. Companies in this sector focus on developing, manufacturing, and marketing a wide range of pharmaceutical products.
Regulatory Implications
As a pharmaceutical company, Endo, Inc. is subject to extensive regulatory scrutiny regarding drug development, manufacturing, marketing, and safety. Compliance with FDA regulations and other health authorities is critical. Changes in healthcare policy or increased litigation related to pharmaceutical products can pose significant risks.
What Investors Should Do
- Review the Proxy Statement thoroughly.
- Vote your shares.
Key Dates
- 2025-06-02: Filing Date — This is the date the definitive proxy statement (DEF 14A) was filed with the SEC, initiating the formal communication process for the annual meeting.
- 2025-06-25: Annual Meeting Date — This is the date of the Annual Meeting of Stockholders, where key corporate decisions and voting will take place.
- 2024-01-01: Compensation Period Start — Marks the beginning of the fiscal year for which executive compensation data, including equity awards, is detailed in the proxy statement.
- 2024-12-31: Compensation Period End — Marks the end of the fiscal year for which executive compensation data, including equity awards, is detailed in the proxy statement.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by public companies to solicit shareholder votes for their annual meetings. (This document is the primary filing for Endo, Inc.'s annual meeting, containing information on proposals, executive compensation, and corporate governance.)
- Proxy Statement
- A document that a company must provide to shareholders before a shareholder meeting, detailing the matters to be voted on. (Essential for shareholders to understand the issues and make informed voting decisions at the Endo, Inc. annual meeting.)
- Equity Awards
- Awards granted to employees, typically executives, in the form of company stock or stock options, often used as part of compensation. (Key components of executive compensation for Mr. Hirsch and Mr. Coleman, as detailed for the 2024 fiscal year.)
- SIC 2834
- Standard Industrial Classification code for Pharmaceutical Preparations, indicating the company's primary business sector. (Identifies Endo, Inc. as a pharmaceutical preparations company, providing context for its industry and operations.)
Year-Over-Year Comparison
This filing, dated June 2, 2025, is a definitive proxy statement for the June 25, 2025, annual meeting. As it focuses on corporate governance and executive compensation for the 2024 fiscal year, it does not provide comparative financial metrics like revenue or net income against a prior year. Specific business changes or new risk factors beyond standard disclosures are not detailed in this particular document.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 2, 2025 by Paul Herendeen regarding Endo, Inc..